Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.39 |
| ▸ | AVPR1B | P47901 | 3/20 | 0.35 |
| ▸ | OXTR | P30559 | 2/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL720919 | 0.90 | GPR119 (0.39) | GPR119PTGS2GHSR | |
| SCHEMBL720852 | 0.86 | GPR119 (0.51) | GPR119PTGS2MEN1LMNAPKM | |
| SCHEMBL718508 | 0.80 | GPR119 (0.49) | GPR119 | |
| SCHEMBL719659 | 0.80 | GPR119 (0.49) | GPR119 | |
| SCHEMBL718507 | 0.80 | GPR119 (0.49) | GPR119 | |
| SCHEMBL719546 | 0.77 | RAB9A (0.40) | GPR119 | |
| SCHEMBL721511 | 0.77 | GPR119 (0.46) | GPR119LMNAPKM | |
| SCHEMBL717665 | 0.74 | KMT2A (0.43) | GPR119MEN1LMNAKMT2A | |
| Tert-Butyl Formate SCHEMBL27789521 | 0.73 | AOC3 (0.44) | AVPR1BOXTRAVPR1AJAK2JAK1 | |
| SCHEMBL719355 | 0.73 | GPR119 (0.38) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | GPR119, GLP1R, GIPR | GPR119 1/4885AVPR1B 340/4885OXTR 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.